Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

Inclusion Criteria: * Pathologically confirmed diffuse large B-cell lymphoma (DLBCL); * Have a "measurable lesions" ; * Have at least one of the following risk factors, including: IPI score ≥2 points, ABC subtype, double-expressor lymphoma, double-hit lymphoma, CD5-positive DLBCL, MCD subtype, N1 subtype, A53 subtype, extranodal lesions ≥2, special site involvement, such as central nervous system CNS, breast, testis, ovary, uterus, bone marrow, vitreoretinal, paraspinal, paranasal sinuses and intravascular, etc. * ECOG score 0-3; * Expected survival time for 3 months or more; * White blood cell count ≥3 x 10e9/L, the platelet count≥50 x 10e9/L; 1.5 mg/dL or less of serum creatinine, creatinine clearance≥50 ml/min; ALT, AST 3 x ULN or less, total bilirubin 2 x ULN or less. Exclusion Criteria (the subject should not have any one of the following): * currently suffering from other malignant tumor; * ever received any treatments for lymphoma, except for short-term use of corticosteroids; * Allergic to any kind of study drug; * Active infection or uncontrol of HBV infection, HIV/AIDS or other serious infectious diseases; * Pregnancy and lactation women of childbearing age and are reluctant to take contraception subjects; * Researchers think that the subject does not fit to participate in this study.